Active Ingredient History

  • Now
Funapide (INN) is a novel analgesic under development by Xenon Pharmaceuticals for the treatment of a variety of chronic pain conditions, including osteoarthritis, neuropathic pain, postherpetic neuralgia, and erythromelalgia, as well as dental pain. It acts as a small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker. Funapide is being evaluated in humans in both oral and topical formulations, and as of July 2014, has reached phase IIb clinical trials.   Wikipedia

  • SMILES: FC(F)(F)c1oc(CN2C(=O)[C@@]3(COc4cc5OCOc5cc34)c6ccccc26)cc1
  • Mol. Mass: 429.35
  • ALogP: 4.25
  • ChEMBL Molecule:
More Chemistry
funapide | tv-45070 | xen-401-s | xen-402 | xpf-002


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue